Medicare Part D Plans Want Preferred Specialty Tier
But Not Limited To Generics And Biosimilars
Executive Summary
Payers say Part D plans should have flexibility in determining which drugs to place on a preferred specialty tier, while manufacturers oppose the notion of a second specialty tier altogether.